Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Signed informed consent.
Subjects who have participated in Study MHE100185 and have been administered at least 2 doses of study medication.
Not pregnant or nursing
Of non-childbearing potential (i.e., women who had a hysterectomy, are post-menopausal which is defined as 1 year without menses, have both ovaries surgically removed, or have current documented tubule ligation); or
Of childbearing potential (i.e., women with functional ovaries and no documented impairment of oviductal or uterine function that would cause sterility). This category includes women with oligomenorrhoea \[even severe\], women who are perimenopausal or have just begun to menstruate. These women must have a negative serum pregnancy test at the Screening Visit, and agree to one of the following:1). Complete abstinence from intercourse from 2 weeks prior to administration of the first dose of investigational product until 3 months after the last dose of investigational product; Or 2). Consistent and correct use of one of the following acceptable methods of birth control for one month prior to the start of the investigation product and three months after the last dose:Male partner who is sterile prior to the female subject's entry into the study and is the sole sexual partner for the female subjects; Implants of levonorgestrel;Injectable progestogen;Any intrauterine device (IUD) with a documented failure rate of less than 1% per year; Oral contraceptives (either combined or progestogen only)
You may not be if
Has developed life-threatening or other serious illness or clinical manifestation deemed inappropriate for inclusion in study per the principal investigator
Has any of the following abnormal laboratory values at the Week36/EW Visit of Study MHE100185: • Serum creatinine ≥3 times institutional upper limit normal (ULN); • AST or/ALT ≥5 times institutional ULN; • Platelet count \< 50,000/uL
Has developed abnormal cardiac functions, as the following, within past 3 months:• Left ventricular ejection fraction (LVEF) \< 20%; • NYHA class IIIb or IV; • Angina or acute myocardial infarction
Has developed allergic reaction to Study MHE100185 investigational product Use of an investigational drug as concurrent medication
Does not complete Week36/EW Visit assessments required in Study MHE100185
Has completed or been terminated from Study MHE100185 for more than 1 month
Recent history or suspicion of current drug abuse or alcohol abuse within the last 6 months
Positive pregnancy test at the Week36/EW Visit of Study MHE100185
Clareo Health | Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome
